We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
-2.91%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$136M
AUM Growth
-$30M
(-18%)
Cap. Flow
-$21.6M
Cap. Flow
% of AUM
-15.92%
Top 10 Holdings %
Top 10 Hldgs %
25.49%
Holding
262
New
34
Increased
55
Reduced
87
Closed
45
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Enovis
ENOV
|
+$1.04M |
| 2 |
Amphastar Pharmaceuticals
AMPH
|
+$1.04M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$958K |
| 4 |
Invesco NASDAQ 100 ETF
QQQM
|
+$955K |
| 5 |
Sarepta Therapeutics
SRPT
|
+$929K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UroGen Pharma
URGN
|
+$2.16M |
| 2 |
Corcept Therapeutics
CORT
|
+$2.14M |
| 3 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
+$2.13M |
| 4 |
KALV
KalVista Pharmaceuticals
KALV
|
+$1.49M |
| 5 |
Perspective Therapeutics
CATX
|
+$1.35M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 60.25% |
| 2 | Real Estate | 12.98% |
| 3 | Financials | 6.42% |
| 4 | Industrials | 2.59% |
| 5 | Technology | 2.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Uber
UBER
$147B
| – | – |
-2,649
| Closed | -$204K |
|
|
252
UroGen Pharma
URGN
$1.96B
| – | – |
-143,898
| Closed | -$2.16M |
|
253
State Street SPDR FTSE International Government Inflation-Protected Bond ETF
WIP
$492M
| – | – |
-2,481
| Closed | -$99.2K |
|
254
Wynn Resorts
WYNN
$10B
| – | – |
-672
| Closed | -$68.7K |
|
|
ASXC
255
DELISTED
Asensus Surgical, Inc.
ASXC
| – | – |
-250,000
| Closed | -$57.5K |
|
|
DCPH
256
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| – | – |
-60,000
| Closed | -$944K |
|
|
SWAV
257
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| – | – |
-120
| Closed | -$39.1K |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q2 2024 Portfolio in Review
As of Q2 2024, AlphaCentric Advisors held 262 positions worth $136M, down 18% from $166M the previous quarter. Its ten largest holdings account for 25% of the portfolio.
AlphaCentric Advisors withdrew a net $21.6M in Q2 2024, closing 45 positions and reducing 87 holdings. Its most notable exit was UroGen Pharma, an estimated $2.16M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 61% a quarter earlier, followed by Real Estate and Financials.
Against the trend, AlphaCentric Advisors opened a new position in Enovis worth $904K.
- AlphaCentric Advisors's largest Q2 2024 buy was Enovis: 20,000 shares worth $904K.
- AlphaCentric Advisors added most to Invesco QQQ Trust in Q2 2024, an estimated $958K increase.
- AlphaCentric Advisors's biggest Q2 2024 reduction was Inari Medical, Inc. Common Stock, cutting an estimated $2.13M.
- AlphaCentric Advisors fully exited UroGen Pharma in Q2 2024, selling an estimated $2.16M.
- AlphaCentric Advisors's ten largest holdings make up 25% of its $136M portfolio in Q2 2024.
- AlphaCentric Advisors opened 34 new positions and closed 45 in Q2 2024.
- AlphaCentric Advisors's portfolio value fell 18% quarter-over-quarter to $136M.
Based on AlphaCentric Advisors's 13F filing for Q2 2024, filed 25 Jul 2024.